Targovax (TRVX) Småprat

[Xon]

Du forklarer selvfølgelig …

[Whatsthat]

Combination trial could be start of second act for Amgen’s Imlygic

[Ramsess]

Det er nok noen som er redd dataene skal slå negativt ut, eller selge på news.

Edit:
Men skal en tolke smilefjesene i dag, tror jeg ikke det

[Chrysler300C]

Det er vel bare emi gutta som skal ut ! Får håpe de står for mesteparten av salg på mandagens liste

[BioMed]

Vi tror at aksjekursen kan være på et vendepunkt, da mange kliniske prøveutlesninger nærmer seg

Targovax: Clinical data approaching

[Krieghoff]

Dagens fra DnB,

Targovax reported an operating loss of NOK40m for Q1, bang in line with our estimate. On the conference call, management highlighted prospects of near-term readouts from several clinical studies. It also said data from the mesothelioma trial will be presented around New Year 2020, sooner than previously communicated. We keep our BUY recommendation but have cut our target price to NOK10.5 (13) following the recent private placement.

Q1 operating loss of NOK40m . Including the recently received proceeds from the private placement, Targovax had cash of NOK172m at end-Q1, enough to run operations towards the end of 2020 on our calculations.

We expect a lot of near term news flow from clinical activities . Management said on the Q1 conference call that it expects to communicate the data readout from the Melanoma trial with ONCOS-1012 before the end of June this year. The data will focus on ORR and immune response in patients from the first cohort of the study. The company is aiming to present 3-year survival data from the phase I/II trial with TG01 in patients with resected pancreatic cancer in about two weeks. What caught our attention during the conference call was that randomised data from the ONCOS-102 phase IB/II trial in unresectable mesothelioma will be presented around New Year 2020, according to management, sooner than had previously has been communicated and a result of faster patient recruitment than expected. On 8 May Targovax reported that enrolment in the study had been completed and it is now awaiting 6-month survival data from all patients before the readout can be communicated.

Out-licensing to Zelluna Immunotherapy . During Q1, Targovax granted Zelluna Immunotherapy an FRO licence to the intellectual property relating to mutant RAS T-cell receptor technology. During the conference call, management clarified that it does not expect any milestone payments from this deal near-term, but that it would have an option to participate in Zelluna Immunotherapy’s potential future success with its technology.

We reiterate our BUY recommendation but have cut our target price to NOK10.5 as a result of the average number of shares rising from c52.6m to c63.1m following the recent private placement.

[TekBot]

10/05-2019 07:00:06: (TRVX) Targovax ASA: Commencement of subscription period in the subsequent offering

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

Oslo, 10 May 2019: Reference is made to the stock exchange announcement by
Targovax ASA (OSE: TRVX) (“Targovax” or the “Company”) on 27 March 2019
regarding the subsequent offering (the “Subsequent Offering”) and listing of up
to 2,104,394 new shares in the Company each with a par value of NOK 0.10 (the
“Offer Shares”) and the stock exchange announcement by the Company on 9 April
2019 regarding the proposal to re-schedule the subscription period in the
Subsequent Offering.

The subscription period in the Subsequent Offering commences today, on 10 May
2019, and will expire on 24 May 2019 at 16:30 hours (CEST). Subscription Rights
that are not used to subscribe for Offer Shares before 16:30 hours (CEST) on 24
May 2019 will have no value and will lapse without compensation to the holder.

DNB Markets is acting as manager in the Subsequent Offering.

For more information, please see the prospectus of the Company dated 27 March
2019 and the supplemental prospectus dated 12 April 2019. The prospectus and the
supplemental prospectus, including the subscription form, is available at the
following websites: www.targovax.com and www.dnb.no/emisjoner

For further information, please contact:

Torbjørn Furuseth, CFO
Phone: +47 932 11 101
Email: torbjorn.furuseth@targovax.com

About Targovax

Activating the patient’s immune system to fight cancer Targovax (OSE:TRVX) is a
clinical stage biotechnology company developing immune activators to target hard
-to-treat solid tumors. Immuno-oncology is currently one of the fastest growing
therapeutic fields in medicine.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect and
replicate in cancer cells. It has been shown to activate the immune system to
generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced
both local and systemic innate and adaptive immune activation, which has been
associated with clinical benefit. ONCOS-102’s targeted path-to-market indication
is mesothelioma, where the virus is currently being tested in a randomized phase
II trial. Another trial, in checkpoint inhibitor refractory advanced melanoma,
is expected to produce important proof-of-concept immune activation data in
heavily pre-treated patients.

Targovax is also developing a neo-antigen cancer vaccine targeting tumors with
oncogenic RAS-mutations, which are known to drive cancer. The TG vaccine program
has shown strong RAS-specific immune activation and a signal of clinical
efficacy in a 32-patient trial with TG01 in resected pancreatic cancer. A next
generation product candidate, TG02 is currently tested in a phase I trial in
colorectal cancer, both as monotherapy and in combination with Keytruda (an anti
-PD1 check point inhibitor).

IMPORTANT INFORMATION

These materials do not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the “U.S.
Securities Act”). The securities of the Company have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Directive, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State. The expression “Prospectus
Directive” means Directive 2003/71/EC as amended (together with any applicable
implementing measures in any Member State.

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). These materials are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.

Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.

Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The
Managers are acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Managers nor any of their respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the
Managers nor any of their respective affiliates accepts any liability arising
from the use of this announcement.

Each of the Company, the Managers and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

This information is subject to disclosure requirements pursuant to Section 5-12
of the Norwegian Securities Trading Act.

http://www.netfonds.no/quotes/release.php?id=20190510.OBI.20190510S4

[Hod]

Ikke lett å vite hva man skal gjøre når kursen er 6,30, reparasjonsaksjer til 7kr og mellom der en avlesning som kan trigge opp eller ned. Snittet ned i går, bare 9,90 i kostpris

[Cinvest]

Sånn, da fikk jeg tid til å¨skrive det som var tiltenkt. Årsaken til at ledelsen ønsket å utvide tegningsperioden var vell nettopp for at vi skulle få TG01 meldingen først, i håp om at det skulle booste kursen over de 7kr som reperasjonsaksjene er satt til. Aksjonærvennlig tanke. Jeg håper jo de får inn de pengene, men er selv usikker på hva jeg skal gjøre med aksjene per nå, ettersom vi er under tegningskursen. Forhåpentligvis flyr vi over 7kr, slik at det blir et godt kjøp, og ledelsen får inn de sårt trengte pengene

[hansi]

Jeg har nå tegnet meg, det er jo mulig å annullere om kursen ikke når over 7,-

[busk1]

Det bruker ikke å være mulig å trekke tilbake tegningen etter at det er sendt inn.

Se tegningsskjemaet like over signaturfeltet:

I/we hereby irrevocably (i) apply for the number of Offer Shares specified above subject to the terms and conditions set out in this Subscription Form and in the Prospectus,

Irrevocably = ugjenkallelig

Edit: og det står det samme litt lenger oppe på skjemaet

Subscriptions are irrevocable and binding upon receipt and cannot
be withdrawn, cancelled or modified by the subscriber after having been received by DNB Markets, or in the case of subscriptions through the VPS online subscription system, upon
registration of the subscription.

[Legoland]

Avventer först Q1 for Pho og nyheter fra Trvx för jeg bestemmer meg om aa nulle ut, bruke rettene eller overtegne. Ett eller annet sted maa ev penger tas.

[Whatsthat]

Igår sa de at dataene kommer om 2 uker (ca?). Det vil si 23 mai, tilfeldigvis samme dag som Magnus skal på AX Exposure, live webcast… mulighet for å tenge seg aksjer på nok 7 går ut 24 Mai… tipper det blir en ganske heftig volum den 23 da… får håpe man blir kvitt de kortsiktige i samme slengen…

[hansi]

ok, takk busk1. Så bare i VPS at det var en knapp det sto “annuller” på.

[Xon]

Har du mottatt skjema i posten ?

[busk1]

Nei. Fant det her.

[Ramsess]

For min egen del er jeg villig til å ta ett (midlertidig) papirtap for at selskapet kan få frisk kapital rett i kassa. Dette skjer jo som kjent ikke om man kjøper i markedet.

[1mattis1]

Vil først se an en evt. positiv/negativ mld.
Er egentlig fullastet, men…

[Whatsthat]

Hva vil være positivt/negativt?

9/13 fra 2 års ilivet…

Realistisk så tenker jeg vi har 5-6 av 13 ilivet for cohort2. Håpet selvsagt på 7+/13 for lengere mOS…

[aborum]

Mit perspektiv for at akkumulere på 6-tallet er, at det er ganske få uger siden, aktien blev handlet i rekordhøj volumen på 11-tallet (endda med forestående emission …). Her ser man nu dagligt aktører i markedet sælge store poster på 6-tallet … uden forestående emission.

Jeg satser på gode data fra TG-01 3-års udlæsning. Det er svært at se, hvordan det videre forløb for TG-01 ser ud, men aftalen med Parker og CRI har vist, at der rent klinisk er stor interesse for de resultater, selskabet har præsteret. Det er min vurdering, at denne interesse på sigt kan og bør blive omsat til interesse fra BP - og blive en gevinst for patienterne.

En tydelig 3-års forsættelse af “halen” jfr. 2-års udlæsningen vil nok tiltrække sig stor opmærksomhed og med rimelighed bruges som forhandlingsgrundlag overfor en partner, der enten ønsker at tage TG-01 ind i egen portefølje eller indgå i et samarbejde om et større klinisk studie (med mDFS som endepunkt jfr. Sougs udtalelser på Q4 præsentationen).

I tillæg til ovenstående har ledelsen jo indikeret en relativ stærk nyhedsstrøm for resten af 2019, så jeg ser personligt ikke nogen udfordringer i at akkumulere med 10 - 15% rabat på emissionsniveauet.